Screener
Theravance Biopharma TBPH Total Equity
Total Equity at other companies
Other financials
Where this comes from
Reported directly by Theravance Biopharma in its filing.
Tagged under the XBRL concept us-gaap:StockholdersEquity.
The source filing: Theravance Biopharma’s 10-Q, filed May 7, 2026.
- Filed
- May 7, 2026, 9:00 AM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001104659-26-056760
| Line item | March 31, 2026 | December 31, 2025 |
|---|---|---|
| Shareholders’ Equity | ||
| Preferred shares, $0.00001 par value per share: 230 shares authorized, no shares issued or outstanding | — | — |
| Ordinary shares, $0.00001 par value per share: 200,000 shares authorized; 51,515 and 51,069 shares issued and outstanding at March 31, 2026 and December 31, 2025, respectively | 1 | 1 |
| Additional paid-in capital | 1,155,215 | 1,156,288 |
| Accumulated other comprehensive income | (62) | 61 |
| Accumulated deficit | (864,560) | (859,627) |
| Total shareholders’ equity | 290,594 | 296,723 |
| Total liabilities and shareholders’ equity | $472,313 | $485,570 |
Item 1. Financial Statements (unaudited)
FAQ
- What is Theravance Biopharma's total equity?
- Theravance Biopharma (TBPH) reported total equity of $290.59M in Q1 2026.
- How has Theravance Biopharma's total equity changed year-over-year?
- Theravance Biopharma's total equity increased by 75.1% year-over-year, from $165.98M to $290.59M.
- What is the long-term trend for Theravance Biopharma's total equity?
- Over 5 years (2020 to 2025), Theravance Biopharma's total equity has grown at a -0.5% compound annual growth rate (CAGR), from -$303.75M to $296.72M.
- What does total equity mean?
- Net assets attributable to shareholders — total assets minus total liabilities. Represents the book value of shareholders' ownership claim.
Ask your AI about Theravance Biopharma's total equity.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude